Pelthos Therapeutics Inc. engaged Grant Thornton LLP as its auditor.
“Also on May 16, 2026, the Audit Committee approved the engagement of Grant Thornton LLP (“Grant Thornton”), as its new independent registered public accounting firm.”
Pelthos Therapeutics Inc. — fact timeline
Source-grounded facts extracted from Pelthos Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Pelthos Therapeutics Inc. dismissed CBIZ CPAs P.C. as its auditor.
“On May 16, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Pelthos Therapeutics Inc. (the “Company”) approved the dismissal of CBIZ CPAs P.C. (“CBIZ”), as the Company’s independent registered public accounting firm.”
Francis Knuettel II was terminated as Chief Financial Officer, Treasurer and Secretary at Pelthos Therapeutics Inc..
“the Board terminated Francis Knuettel II from his position as Chief Financial Officer, Treasurer and Secretary of the Company, effective April 10, 2026.”
Pelthos Therapeutics Inc. reported first quarter ended March 31, 2026 results: revenue $10.7 million, net income $(10.2) million.
“Therapeutics Announces First Quarter 2026 Financial Results ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units”
Pelthos Therapeutics Inc. reported financial results for fourth quarter and full year ended December 31, 2025.
“Pelthos Therapeutics Inc. (the “Company”) issued a press release summarizing its financial results for the three months and year ended December 31, 2025”
Pelthos Therapeutics Inc. entered into Venture Loan and Security Agreement with Horizon Technology Finance Corporation valued at aggregate principal amount of up to $50.0 million (effective 2026-01-12).
“On January 12, 2026 (the “ Closing Date ”), Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), LNHC, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ LNHC ”) and Channel Pharmaceutical Corporation, a Nevada corporation and a wholly subsidiary of the Company (“ Channel ”), as co-borrowers (together with the Company, the “ Borrowers ”), entered into a Venture Loan and Security Agreement (the “ Loan Agreement ”) by and among the Borrowers and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “ Lender ”).”
Pelthos Therapeutics Inc. entered into Asset Purchase Agreement with Hatchtech Pty Ltd valued at $1,800,000 aggregate purchase price (including $450,000 down payment paid on November 20, 2025 and $ (effective 2025-12-23).
“On December 23, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”) entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) with Hatchtech Pty Ltd ACN 098 559 409, an Australian corporation (“ Hatchtech ”), pursuant to which Hatchtech sold all of its right, title and interest in (i) the product developed by Hatchtech with Abametapir as its sole active ingredient for the treatment of head lice infestation in humans (the “ Xeglyze Product ”), (ii) all intangible assets of Hatchtech including intellectual property of Hatchtech relating to the Xeglyze Product, including, without limitation (A) certain patent and patent applications, together with all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, and renewals and (B) certain trademarks, service marks, trade names and registered user names, including registrations and applications for registration thereof, together with all goodwill associated therewi”
Pelthos Therapeutics Inc. issued $18.0 million aggregate original principal amount of senior secured convertible notes convertible into shares of common stock at $34.442 per share of convertible note to certain investors including Ligand Pharmaceuticals Incorporated for cash gross proceeds of approximately $18.0 million, plus a 5.0% royalty on net sales of Xepi and the right to receive Sato Payments.
“On November 6, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain investors, including Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Ligand ”) (collectively, the “ Investors ”), pursuant to which, among other things, on the Closing Date, the Investors purchased for cash, and the Company issued and sold to the Investors, senior secured convertible notes of the Company (the “ Convertible Notes ”) in the aggregate original principal amount of $18.0 million, which are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) (such transaction, the “ Convertible Note Financing ”).”
Pelthos Therapeutics Inc. incurred convertible notes of $18.0 million with Investors, including Ligand Pharmaceuticals Incorporated at 8.5% per annum (increases to 18.0% in the event of default) maturing November 6, 2027.
“On November 6, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain investors, including Ligand Pharmaceuticals Incorporated, a Delaware corporation (“ Ligand ”) (collectively, the “ Investors ”), pursuant to which, among other things, on the Closing Date, the Investors purchased for cash, and the Company issued and sold to the Investors, senior secured convertible notes of the Company (the “ Convertible Notes ”) in the aggregate original principal amount of $18.0 million, which are convertible into shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) (such transaction, the “ Convertible Note Financing ”).”
Pelthos Therapeutics Inc. completed an acquisition involving LNHC, Inc. and Ligand Pharmaceuticals Incorporated (closed 2025-07-01).
“On July 1, 2025, Channel Therapeutics Corporation, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand consummated the Merger”
Pelthos Therapeutics Inc.: Company effected a reverse stock split at a 1:10 ratio effective July 1, 2025 (effective 2025-07-01).
“the Company effected the Reverse Stock Split pursuant to the Reverse Stock Split Certificate of Amendment.”
Pelthos Therapeutics Inc.: Company changed name from Channel Therapeutics Corporation to Pelthos Therapeutics, Inc.
“the Company changed its name from “Channel Therapeutics Corporation” to “Pelthos Therapeutics, Inc.” pursuant to the Name Change Certificate of Amendment.”
Pelthos Therapeutics Inc. engaged CBIZ CPAs P.C. as its auditor.
“On April 11, 2025, with the approval of Channel’s Board of Directors, CBIZ was engaged as Channel’s independent registered public accounting firm.”
Marcum LLP resigned as auditor of Pelthos Therapeutics Inc..
“On April 11, 2025, Channel was notified by Marcum that Marcum resigned as Channel’s independent registered public accounting firm.”
Pelthos Therapeutics Inc. incurred loan of $325,000 with 3i, L.P. at 6.0% maturing May 25, 2025.
“On February 25, 2025, Channel Therapeutics Corporation (the “Company”) issued an unsecured promissory note in the aggregate principal amount of $325,000 (the “Note”) to 3i, L.P., a Delaware limited partnership (the “Holder”), for a purchase price of $250,000, pursuant to which the Company promises to pay the Holder or its registered assigns the principal sum of $325,000 or such amount equal to the outstanding principal amount of the Note together with interest. The Note will bear interest on the outstanding principal amount at an annual rate equal to 6.0%. The Note may be prepaid by the Company without penalty, in whole or in part, upon two days’ prior written notice to the Holder. All unpaid principal, together with any then unpaid and accrued interest and other amounts payable under the Note, will otherwise be due and payable on the earliest of: (i) May 25, 2025, (ii) the consummation of a Corporate Event (as defined in the Note), or (iii) when, upon or after the occurrence of an Eve”
Pelthos Therapeutics Inc.: Changed company name to Channel Therapeutics Corporation as part of reincorporation (effective 2024-11-18).
“As a result of the Reincorporation, as of the Effective Time, the Predecessor Registrant changed its name to “Channel Therapeutics Corporation” (the “ Name Change ”) pursuant to the Nevada Articles and Nevada Charter, filed with the with the Secretary of State of the State of Nevada on November 18, 2024 and November 5, 2024, respectively.”
Pelthos Therapeutics Inc.: Reincorporation and name change to Channel Therapeutics Corporation under Nevada charter (effective 2024-11-18).
“As a result of the Reincorporation, as of the Effective Time, the Predecessor Registrant changed its name to “Channel Therapeutics Corporation” (the “ Name Change ”) pursuant to the Nevada Articles and Nevada Charter, filed with the with the Secretary of State of the State of Nevada on November 18, 2024 and November 5, 2024, respectively.”
Francis Knuettel II was appointed as Chief Executive Officer at Pelthos Therapeutics Inc..
“The board of directors (the “Board”) of Chromocell Therapeutics Corporation (the “Company”) has appointed Francis Knuettel II as Chief Executive Officer of the Company, effective March 13, 2024.”
Pelthos Therapeutics Inc.: Amended and Restated By-laws became effective on February 15, 2024, in connection with the pricing of the Initial Public Offering (effective 2024-02-15).
“On February 15, 2024, the Company’s Amended and Restated By-laws (the “Restated By-laws”) became effective in connection with the pricing of the Initial Public Offering.”
Pelthos Therapeutics Inc.: Filed amended and restated certificate of incorporation effective upon pricing of Initial Public Offering on February 15, 2024, including a 1-for-9 reverse stock split (effective 2024-02-15).
“On February 15, 2024, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the pricing of the Initial Public Offering.”
Pelthos Therapeutics Inc. entered into Underwriting Agreement with A.G.P./Alliance Global Partners (effective 2024-02-15).
“On February 15, 2024, Chromocell Therapeutics Corporation, a Delaware corporation (the “Company”) entered into an underwriting agreement, as amended by that certain Letter Agreement, dated February 16, 2024 (together, the “Underwriting Agreement”) with A.G.P./Alliance Global Partners, as the representative of the underwriters named therein (the “Representative” or, the “Underwriter”), relating to the issuance and sale by the Company to the Underwriter (the “Initial Public Offering”) of an aggregate of 1,100,000 shares (the “Shares”) of the Company’s common stock”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.